Aesthetics attended aesthetic distributor Healthxchange’s official UK&I launch of Potenza at Bacchanalia in Mayfair. Officially manufactured by aesthetic manufacturer Jeisys, the evening featured Potenza key opinion leaders international dermatologist Dr
Aesthetic distributor ACRE has revealed distribution partnerships with pharmaceutical company IBSA Derma and skincare brand ZO Skin Health. IBSA Derma shares that ACRE’s pharmaceutical expertise, trusted service model and deep
Verification and consumer education platform Twiqk welcomed specialty guests to its inaugural Twiqk Preview event at Stationers’ Hall in London. Sponsored by Japanese wellness brand Yotsuba, the event featured panel
Platelet-rich plasma (PRP) training provider PRP Pure has announced two new injectables to officially launch at the Clinical Cosmetic Regenerative Congress (CCR) 2026. The first launch taking place is EXOBIOFILLER,
The British College of Aesthetic Medicine (BCAM) has urged patients to prioritise safety when considering steroid injections for hay fever relief. BCAM shares that, following reports of growing popularity, some
Skincare company SkinCeuticals hosted press and practitioners to present its newly launched P-TIOX Cream and the next generation of PHYTO CORRECTIVE on July 14. The morning opened with David McNulty-Ringshaw,
Aesthetics attended the launch of Versatile Bronze Shade + Sculpt by skincare makeup brand et al., distributed by International Institute for Active Ageing (iiaa), at The Beauty Edit Mayfair on
Pharmaceutical company Evolus hosted an event at the Everyman Cinema for the launch of injectable hyaluronic acid Estyme on July 6. Opening the event, Dallas Waltham, marketing manager at Evolus
Biotechnology company Absci has released positive interim Phase 1 data from its first-in-human trial of investigational anti-prolactin receptor (PRLR) antibody ABS-201. The company details that ABS-201 is an experimental antibody
Pharmaceutical company Allergan Aesthetics, an AbbVie company, has announced that the European Commission has approved trenibotulinumtoxinE ‘Boey’ in Europe. The company shares that Boey is the first rapid-onset and short-duration
